PI3Kδ Inhibitor Design via Purine Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory disorders, immune-based diseases, and cancer lack effective agents that specifically target phosphoinositide 3-kinases (PI3Ks), leading to inadequate suppression or augmentation of immune and inflammatory pathways.
Innovation Solution
Development of N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amine derivatives that modulate PI3K activity, specifically inhibiting PI3Kδ kinase to treat diseases associated with abnormal PI3K expression or activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory disorders and immune-based diseases are used, then general immune suppression is achieved, but specific targeting of PI3K pathways is insufficient
Solution Approach 1:
The patent segments the broad immune system into specific PI3K isoforms (PI3Kγ and PI3Kδ) that can be selectively targeted. The compound structure is designed to specifically inhibit these isoforms while sparing other immune pathways, achieving targeted therapy rather than general immune suppression.
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular characteristics that bind preferentially to PI3Kγ and PI3Kδ isoforms. The substituted-phenylethyl-purine structure provides localized chemical properties that enable selective interaction with these specific kinase targets.
2Adaptability or versatility
If non-selective immune suppressants are used, then broad immune pathway suppression occurs, but PI3K-specific inhibition is not achieved
Solution Approach 1:
The patent employs dynamic selectivity where the compound can adapt its binding preference based on the specific PI3K isoform present. The molecular structure allows for dynamic interaction with different isoforms while maintaining preferential binding to PI3Kγ and PI3Kδ, enabling selective inhibition without requiring complete coverage of all immune pathways.
3Reliability
If existing cancer treatments are used, then general anti-cancer effects are achieved, but specific targeting of PI3K-driven oncogenesis is insufficient
Solution Approach 1:
The invention extracts and targets the specific PI3K signaling pathway that drives cancer progression, separating it from other cancer-related pathways. By specifically inhibiting PI3Kγ and PI3Kδ, the compound isolates and addresses the PI3K-driven oncogenic mechanism without requiring broad-spectrum anti-cancer activity.
Solution Approach 2:
The patent utilizes parameter changes in the compound's molecular structure (substituted-phenylethyl-purine framework) to optimize binding affinity and selectivity for PI3K isoforms. By adjusting chemical parameters such as substituent groups and molecular geometry, the compound achieves enhanced specificity for PI3K-driven cancer pathways.
Data Source
AI summary
The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.